Retrovir introduction at Dartford.

Date:
1986
  • Videos
  • Online

Available online

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

You can use this work for any purpose, as long as it is not primarily intended for or directed to commercial advantage or monetary compensation. You should also provide attribution to the original work, source and licence. Read more about this licence.

Credit

Retrovir introduction at Dartford. Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Source: Wellcome Collection.

About this work

Description

This short corporate film with a female voiceover shows the manufacturing processes involved in the drug Retrovir. Barry Alcock in charge of Primary Manufacturing at Dartford describes how the drug was introduced, Dave Lemon describes how they met a tight manufacturing deadline, Doug Faulkner talks about quality assurance and Jeff Waddingham, Retrovir Supplies Coordinator, discusses how the product will effectively reach the rest of the world. 2 segments.

Publication/Creation

London : Wellcome Trust Foundation, 1986.

Physical description

1 encoded moving image (7 min.) : sound, color

Contributors

Duration

00:07:26

Copyright note

Wellcome Trust Foundation; Wellcome Trust 2008

Terms of use

Unrestricted
CC-BY-NC
Creative Commons Attribution-Non-Commercial 2.0 UK: England & Wales

Language note

In English.

Creator/production credits

Produced by the Wellcome Trust.

Contents

Segment 1 Over images of laboratory work and equipment, a voiceover explains how the introduction of a new pharmaceutical item onto the market takes much time and effort and now it normally takes years for the process to be complete. She then goes on to talk about how in September 1986 a double blind clinical study to evaluate the drug Retrovir was stopped because it was obvious it helped in stopping mortality in patients. Production of the drug became a priority for Wellcome. Barry Alcock, in charge of Primary Manufacturing at the Dartford plant, describes how the plant was adapted to cope with the new product. Dave Lemon in the Tablet Manufacturing department describes how capsule making equipment was brought in very quickly. Time start: 00:00:00:00 Time end: 00:03:59:04 Length: 00:03:59:04
Segment 2 Due to the urgency placed on immediate manufacturing of Retrovir, production of capsules went ahead immediately. Doug Faulkner from the Quality Assurance department explains how the first batch had to meet standards, and pass 300 analyses. Jeff Waddingham, the Retrovir Supplies Coordinator, describes how orders were processed immediately, how package design could be adapted for different coountries and how distribution to different countries worked. The voiceover explains how usually, a new drug being put onto the market takes about three years, but Retrovir took just six months. All the previously seen Wellcome staff discuss what a challenge this process was and how proud they are to have completed it in time. A note from the Wellcome Trust is shown at the end thanking all the staff who made the introduction of Retrovir a success. Time start: 00:03:59:04 Time end: 00:07:26:24 Length: 00:03:27:19

Type/Technique

Languages

Subjects

Permanent link